Development of gold nanoparticle-based drug carriers for targeted cancer therapy using the Turkevich method.
Original Research
Biomedical & Healthcare
In vitro: MCF-7 and SKOV-3 cell lines, 37°C, 5% CO₂. In vivo: Female BALB/c mice with xenograft tumors, i.v. injection
85% reduction in cancer cell viability with minimal toxicity to healthy cells. 3x higher drug accumulation in tumor tissue. 60% tumor reduction after 4 weeks.
p < 0.001 for tumor reduction vs control (n=15 per group). ANOVA with Tukey post-hoc test.
Successful
Initial batch-to-batch variability in particle size. Optimization of targeting ligand density required multiple iterations.
Clinical trial planning. Investigation of dual-drug loading. Exploring other cancer types.